Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Morrison

Showing results (51-60 of 84) with videos related to

Pageof 9
Sort By:
Journal of Managed Care & Specialty Pharmacy|September 15, 2025
Cost-per-responder analysis of daratumumab, bortezomib, lenalidomide, and dexamethasone vs bortezomib, lenalidomide, and dexamethasone among transplant-eligible patients with newly diagnosed multiple myelomaSantosh Gautam, Laura Morrison, Philippe Thompson-Leduc, et al.
Current Medical Research and Opinion|December 18, 2018
Real-world outcomes post-transition to once-every-3-months paliperidone palmitate in patients with schizophrenia within US commercial plansBruno Emond, Antoine C El Khoury, Charmi Patel, et al.
Journal of Medical Economics|February 23, 2024
Cost of genetic testing, delayed care, and suboptimal treatment associated with polymerase chain reaction versus next-generation sequencing biomarker testing for genomic alterations in metastatic non-small cell lung cancerChristine M Bestvina, Dexter Waters, Laura Morrison, et al.
The Journal of Clinical Psychiatry|April 7, 2022
Economic Burden of Commercially Insured Patients With Major Depressive Disorder and Acute Suicidal Ideation or Behavior in the United StatesDominic Pilon, Cheryl Neslusan, Maryia Zhdanava, et al.
Current Medical Research and Opinion|December 12, 2018
The prospective economic impact of once monthly paliperidone palmitate versus oral atypical antipsychotics in Medicaid patients with schizophreniaAntoine C El Khoury, Dominic Pilon, Laura Morrison, et al.
The Oncologist|July 31, 2024
Treatment patterns for patients with BRCA1/2-positive metastatic castration-resistant prostate cancerMehmet A Bilen, Ibrahim Khilfeh, Carmine Rossi, et al.
Advances in Experimental Medicine and Biology|May 9, 2021
Multimodal Measurements of Brain Tissue Metabolism and Perfusion in a Neonatal Model of Hypoxic-Ischaemic InjuryGemma Bale, Ajay Rajaram, Matthew Kewin, et al.
Journal of Health Economics and Outcomes Research|September 2, 2025
Healthcare Resource Use, Healthcare Costs, and Unmet Needs Among Patients Treated for EGFR-Mutated Advanced or Metastatic Non-small Cell Lung CancerDavid Waterhouse, Iris Li, Laura Morrison, et al.
Pharmacoeconomics|May 27, 2021
Cluster Analysis of Care Pathways in Adults with Major Depressive Disorder with Acute Suicidal Ideation or Behavior in the USAMaryia Zhdanava, Jennifer Voelker, Dominic Pilon, et al.
Journal of Medical Economics|April 21, 2026
Cost-per-responder analysis of TAR-200 versus other Food and Drug Administration-approved novel and generic treatments among patients with Bacillus Calmette-Guérin-unresponsive, high-risk, non-muscle-invasive bladder cancer with carcinoma in situ in the United StatesStephen Williams, Sang Cho, Laura Morrison, et al.
Pageof 9

Showing results (51-60 of 84) with videos related to

Sort By:
Pageof 9
Journal of Managed Care & Specialty Pharmacy|September 15, 2025
Cost-per-responder analysis of daratumumab, bortezomib, lenalidomide, and dexamethasone vs bortezomib, lenalidomide, and dexamethasone among transplant-eligible patients with newly diagnosed multiple myelomaSantosh Gautam, Laura Morrison, Philippe Thompson-Leduc, et al.
Current Medical Research and Opinion|December 18, 2018
Real-world outcomes post-transition to once-every-3-months paliperidone palmitate in patients with schizophrenia within US commercial plansBruno Emond, Antoine C El Khoury, Charmi Patel, et al.
Journal of Medical Economics|February 23, 2024
Cost of genetic testing, delayed care, and suboptimal treatment associated with polymerase chain reaction versus next-generation sequencing biomarker testing for genomic alterations in metastatic non-small cell lung cancerChristine M Bestvina, Dexter Waters, Laura Morrison, et al.
The Journal of Clinical Psychiatry|April 7, 2022
Economic Burden of Commercially Insured Patients With Major Depressive Disorder and Acute Suicidal Ideation or Behavior in the United StatesDominic Pilon, Cheryl Neslusan, Maryia Zhdanava, et al.
Current Medical Research and Opinion|December 12, 2018
The prospective economic impact of once monthly paliperidone palmitate versus oral atypical antipsychotics in Medicaid patients with schizophreniaAntoine C El Khoury, Dominic Pilon, Laura Morrison, et al.
The Oncologist|July 31, 2024
Treatment patterns for patients with BRCA1/2-positive metastatic castration-resistant prostate cancerMehmet A Bilen, Ibrahim Khilfeh, Carmine Rossi, et al.
Advances in Experimental Medicine and Biology|May 9, 2021
Multimodal Measurements of Brain Tissue Metabolism and Perfusion in a Neonatal Model of Hypoxic-Ischaemic InjuryGemma Bale, Ajay Rajaram, Matthew Kewin, et al.
Journal of Health Economics and Outcomes Research|September 2, 2025
Healthcare Resource Use, Healthcare Costs, and Unmet Needs Among Patients Treated for EGFR-Mutated Advanced or Metastatic Non-small Cell Lung CancerDavid Waterhouse, Iris Li, Laura Morrison, et al.
Pharmacoeconomics|May 27, 2021
Cluster Analysis of Care Pathways in Adults with Major Depressive Disorder with Acute Suicidal Ideation or Behavior in the USAMaryia Zhdanava, Jennifer Voelker, Dominic Pilon, et al.
Journal of Medical Economics|April 21, 2026
Cost-per-responder analysis of TAR-200 versus other Food and Drug Administration-approved novel and generic treatments among patients with Bacillus Calmette-Guérin-unresponsive, high-risk, non-muscle-invasive bladder cancer with carcinoma in situ in the United StatesStephen Williams, Sang Cho, Laura Morrison, et al.
Pageof 9